Abbvie IncChange company Symbol lookupSelect an option...ABBV Abbvie IncGVYB Golden Valley BankDHC Diversified Healthcare TrustMGNI Magnite IncINFN Infinera CorpPRSRW Prospector Capital Equity Warrants 1st Jan 2025 *W EXP 01/01/2025HYMCW Hycroft Mining Holding Equity Warrant Exp 29th May 2025 *W EXP 05/29/2025NVOS Novo Integrated Sciences IncTEL TE Connectivity LtdNOTV Inotiv IncGo
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
ABBV's position in the Biotechnology industry
| Industry Peers | GILD | VRTX | REGN | SGEN | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and... | Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral... Go to GILD summary | Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes... Go to VRTX summary | Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines... Go to REGN summary | Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the... Go to SGEN summary |
| 52-Week Change | VS. INDUSTRY | 22.84% | 23.29% | 22.84% | 37.15% |
| Market Cap | VS. INDUSTRY | $95.0B | $85.1B | $82.1B | $36.7B |
| Beta | VS. INDUSTRY | 0.4 | 0.5 | 0.2 | 0.5 |
| Dividend Yield | VS. INDUSTRY | 3.94% | -- | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 17.22x | 26.32x | 20.33x | -- |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $27.0B | $9.2B | $12.4B | $2.1B |
| Profit Margin | VS. INDUSTRY | 20.48% | 35.40% | 33.81% | -31.55% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -13.86% | 65.28% | 23.79% | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | -1.56% | 15.86% | -25.07% | 23.18% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.